Stay ahead of your patients

Meet Sarah*

Consider GILOTRIF first-line for your EGFR M+ mNSCLC patients with a del19 mutation1

Del19
*Not an actual patient
EGFR M+=epidermal growth factor receptor mutation positive;
mNSCLC=metastatic non-small cell lung cancer
Read her story
Meet Lucy*

Consider GILOTRIF as first-line treatment based on its proven efficacy in her specific non-resistant EGFR mutation1

Uncommon EGFR Mutation
*Not an actual patient
EGFR=epidermal growth factor receptor
Read her story
Meet George*

Consider the only FDA-approved oral option for second-line metastatic squamous NSCLC after progression on platinum-based chemotherapy1

Squamous NSCLC
*Not an actual patient
NSCLC=non-small cell lung cancer
Read his story

GILOTRIF: Well established and studied in over 4,200 patients1

LUX-Lung 3
EGFR M+ mNSCLC

Randomized, multicenter, open-label trial that assessed the safety and efficacy of GILOTRIF 40 mg orally once daily (n=230) vs up to 6 cycles of pemetrexed/cisplatin (n=115) as 1st-line therapy in patients with EGFR M+ mNSCLC1

LUX-Lung 8
Squamous mNSCLC

Randomized, multicenter, open-label phase III trial that assessed the safety and efficacy of GILOTRIF 40 mg orally once daily (n=398) vs erlotinib 150 mg once daily (n=397) in patients with metastatic squamous NSCLC with disease progression following ≥4 cycles of platinum-based chemotherapy1

Real-World Evidence with GILOTRIF

Real-World Evidence with GILOTRIF

GioTag

A real-world, global, multicenter, retrospective, observational study conducted through medical records or electronic health records (US only) review of 204 adult patients with EGFR M+ NSCLC (del19/L858R) treated with GILOTRIF followed by osimertinib2

Real GiDo

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC. A non-interventional, observational, global, retrospective study conducted through medical record review of 228 patients enrolled from 13 countries3

Resources for You

del19 Patient Profile
Uncommon EGFR Mutation Profile
Squamous NSCLC Profile
Patient Appointment Checklist
GILOTRIF Clinical Information
Patient Care Guide
GILOTRIF Prescription and Enrollment Form

Resources for Your Patients

GILOTRIF Patient Starter Guide
14-Day Patient Tear Sheets

*Not an actual patient

‡Results are not intended for direct comparison with clinical trials, because the real-world study was an observational trial with no comparator arm. Differences in study designs, patient populations, definitions of safety or efficacy outcomes, as well as data collection methods, make it difficult to compare real-world studies with clinical trials.

References: 1. GILOTRIF [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 2. Hochmair MJ, Morabito A, Hao D, et al. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study [published online October 19, 2018]. Future Oncol. doi:10.2217/fon-2018-0711 3. Halmos B, Tan EH, Soo Ra, et al. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world study (RealGido). Lung Cancer. 2019;127:103-11. 4. Yang JCH, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141-151. 5. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-3334. 6. Ke EE, Zhou Q, Zhang QY, et al. A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R. J Thorac Oncol. 2017;12(9):1368-1375. 7. Data on file. Boehringer Ingelheim. CTR. 8. Lee CK, Wu YL, Ding PN, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J Clin Oncol. 2015;33(17):1958-1965. 9. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX- Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830-838. 10. Yang JCH, Wu JYS, Hsia TC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13:539-548. 11. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213-222. 12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer, version 5. 2018. 13. Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16(8):897 907. 14. Yang JCH, Sequist LV, Zhou C, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 2016;27(11):2103-2110.  15. U.S. Food & Drug Administration (FDA). FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations (press release). https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm592558.htm. Accessed 3.13.2019.

Indications and usage

  • GILOTRIF (afatinib) tablets is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.

    Limitation of Use: Safety and efficacy of GILOTRIF have not been established in patients whose tumors have resistant EGFR mutations.

  • GILOTRIF is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.